TABLE 3.

Clinical studies using CD44‐targeting therapies for cancer treatment.

Form of drug	Cancer applications	Interventions	Phase	NCT No.
Gene‐engineered T cells	CD44v6+ cancer	CD44v6 CAR T cells	I/II	NCT04427449
	Breast cancer	Her2, GD2, and CD44v6 CAR T cells	I/II	NCT04430595
	CD44v6+ acute myeloid leukemia and multiple myeloma	Drug: MLM‐CAR44.1 T cells	I/II	NCT04097301
Humanized mAb	CD44v6+ breast neoplasms	Drug: Bivatuzumab mertansine	I	NCT02254005 NCT02254031
	CD44+ malignant solid tumors	Drug: RO5429083	I	NCT01358903
CD44v6 inhibitor	Malignant solid tumor	Drug: AMC303	I	NCT03009214
	CD44+ ovarian epithelial cancer	Drug: SPL‐108	I	NCT03078400
CD44 binding peptide	Chronic lymphocytic leukemia and small lymphocytic lymphoma	Drug: A6	I	NCT02046928

Data sources: ClinicalTrials. Gov.